Genitourinary Cancers Steering Committee – Bladder Task Force Planning Meeting - Overview


Welcome to the registration site of the NCI’s Genitourinary Cancers Steering Committee’s Clinical Trials Planning Meeting (CTPM) on ‘Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer.'

The purpose of this meeting is to accelerate further advances in clinical trials for patients with high risk including BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). After successful completion of several important clinical trials of novel systemic and intravesical therapies for patients with BCG-unresponsive NMIBC in recent years, further advances are required to improve patient outcomes including disease-free survival. The meeting will focus on the evaluation of strategies incorporating intravesical therapy, systemic therapy, trimodal therapy (incorporating radiation therapy), and combination therapies toward a goal of improving bladder preservation rates and survival outcomes for patients with high risk including BCG-unresponsive NMIBC.

To achieve this goal, the CTPM will bring together experts from across the bladder cancer research community to develop clinical trial concepts in this disease space.

The CTPM will consist of a mixture of talks and Working Group sessions that will endeavor to identify potential strategies and to develop collaborative interdisciplinary approaches to address key questions in the field and propose next generation clinical trial concepts.

We welcome participation from all investigators with an interest in NMIBC clinical trials

General Information

For CTPM related questions, please contact: Abdul Tawab Amiri or Pam West.

Image Credit: Vancouver Prostate Centre / University of British Columbia / Peter Black’s Lab